

## KidneyX Focus Areas + Potential Products

### NEXT-GEN KIDNEY REPLACEMENT

Wearable or implantable dialyzers, bio-artificial kidneys, xenotransplant technology, etc.

### MEDICATIONS

Drugs specifically designed to prevent, treat, and slow progression of kidney diseases, as well as encompass the needs of kidney transplant patients

### DEVICES

Devices that support the management and treatment of kidney diseases that are not dialyzers (such as vascular access technologies, etc.)

### DIAGNOSTICS

Point-of-care or at home testing kits, real time kidney monitoring, etc.

### PATIENT-CENTERED TOOLS

Tools designed to identify and track disease, applications to empower patients to manage kidney diseases (e.g., apps)



Transforming the Development of Kidney Care

40 million Americans live with kidney diseases.  
More than 700,000 Americans have kidney failure.

**There is no cure.**



For more information, please contact  
[kidneyx@asn-online.org](mailto:kidneyx@asn-online.org).

## KidneyX is a public-private partnership to:

- Seed, incentivize, and accelerate breakthroughs in kidney care
- Provide better coordination among HHS, NIH, FDA, and CMS to clear a path towards commercialization
- Create a sense of urgency to bring breakthrough therapies to patients, including fostering multidisciplinary collaboration and engaging the investment community

### What KidneyX Does

- ✓ Incentivizes the accelerated development and commercialization of disruptive solutions
- ✓ Bridges the gap between research and market-ready products
- ✓ Provides merit-based, non-dilutive funding to promising innovators through a series of prize competitions

## KidneyX Features

	<p><b>Public-Private Partnership</b></p> <ul style="list-style-type: none"> <li>• Matching funds from public and private sponsors</li> <li>• Access to a community of investors, business and manufacturing experts, scientists, engineers, patients, payers, and other stakeholders</li> </ul>
	<p><b>Support for Innovative Approaches</b></p> <ul style="list-style-type: none"> <li>• Non-dilutive funding to promising innovators</li> </ul>
	<p><b>Reimagining How HHS Advances Clinical Trials</b></p> <ul style="list-style-type: none"> <li>• Clinical trial co-design with NIH, FDA, and CMS to expedite trials</li> <li>• Engaging CMS early to optimize trial design from coverage standpoint</li> </ul>

### Why KidneyX is Needed

- ✓ Medicare annually spends \$34 billion treating kidney failure
- ✓ Kidney failure is still managed with dialysis, a therapy invented 50 years ago
- ✓ Lack of private investment and venture capital, misaligned public incentives, and a complex regulatory process inhibits innovative ideas from becoming commercially available therapies

### Why KidneyX is the Solution

- ✓ **Achievable:** Similar public-private accelerators have shown immense success, including CARB-X
- ✓ **Comprehensive:** KidneyX will spur innovation across kidney care by supporting the development of improved diagnostics and therapeutics, patient-centered tools to manage kidney diseases, and next-generation dialysis

### How You Can Help

- ✓ **Thank HHS:** Sign letter commending Secretary Azar for HHS commitment to KidneyX
- ✓ **Follow KidneyX:** Subscribe to updates at [www.KidneyX.org](http://www.KidneyX.org) or follow @Kidney\_X on Twitter